Success Metrics

Clinical Success Rate
72.7%

Based on 8 completed trials

Completion Rate
73%(8/11)
Active Trials
0(0%)
Results Posted
88%(7 trials)
Terminated
3(27%)

Phase Distribution

Ph phase_2
3
27%
Ph phase_3
6
55%

Phase Distribution

0

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
6(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(3)

Detailed Status

Completed8
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
72.7%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (33.3%)
Phase 36 (66.7%)

Trials by Status

terminated327%
completed873%

Recent Activity

0 active trials
Showing 5 of 11
terminatedphase_2

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

NCT04854096
completedphase_2

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

NCT03869437
completed

Calcifediol in the Treatment of COVID 19

NCT05819918
terminatedphase_3

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

NCT02055781
completedphase_3

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

NCT02038036
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT04854096Phase 2

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Terminated
NCT03869437Phase 2

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

Completed
NCT05819918

Calcifediol in the Treatment of COVID 19

Completed
NCT02055781Phase 3

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

Terminated
NCT02038036Phase 3

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.

Completed
NCT04167228

Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria

Completed
NCT04358783Phase 2

Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia

Completed
NCT02714595Phase 3

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Completed
NCT01773187Phase 3

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Terminated
NCT02168946Phase 3

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

Completed
NCT01644643Phase 3

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11